TY  - JOUR
AU  - Petrović-Sunderić, Jelena
AU  - Dragičević, Sandra
AU  - Krnjajić, Mina
AU  - Ristanović, Momcilo
AU  - Nikolić, Aleksandra
AU  - Krivokapić, Zoran
PY  - 2018
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/1115
AB  - Purpose: The RAD51 gene plays an important role in homologous strand exchange in DNA repair. Two common single nucleotide polymorphisms in this gene, 135G  gt  C and 172G  gt  T, were associated with altered gene transcription. While 135G  gt  C was already linked to breast and colorectal cancers in certain populations, 172G  gt  T is far less investigated, although sporadic studies showed it could be a prognostic factor for some cancer lesions. The purpose of this study was to investigate RAD51 172G  gt  T polymorphism in Serbian population, its association with colorectal carcinoma, as well as correlation with disease characteristics and response to neoadjuvant chemoradiotherapy. Methods: The 172G  gt  T polymorphism was evaluated by PCR-RFLP method in blood samples of 209 colorectal cancer patients and 43 healthy subjects who served as controls. The distribution of genotypes was also analyzed in respect to several tumor characteristics in cases where histopathological data were available. Results: A significant association between the RAD51 172G  gt  T polymoprhism and desmoplastic reaction of colorectal cancer was demonstrated. The 172G allele was found to be significantly more frequent in patients with more intensive desmoplastic response of the tumor tissue. Conclusions: The results of our study suggest that the 172T allele of RAD51 may be a favorable prognostic factor in Serbian patients with colorectal cancer, although larger prospective studies are required to confirm this finding.
PB  - Balkan Union of Oncology (B.U.ON.)
T2  - Journal of Buon
T1  - Polymorphism RAD51 172G > T in Serbian patients with colorectal cancer
EP  - 940
IS  - 4
SP  - 936
VL  - 23
UR  - https://hdl.handle.net/21.15107/rcub_imagine_1115
ER  - 

@article{
author = "Petrović-Sunderić, Jelena and Dragičević, Sandra and Krnjajić, Mina and Ristanović, Momcilo and Nikolić, Aleksandra and Krivokapić, Zoran",
year = "2018",
abstract = "Purpose: The RAD51 gene plays an important role in homologous strand exchange in DNA repair. Two common single nucleotide polymorphisms in this gene, 135G  gt  C and 172G  gt  T, were associated with altered gene transcription. While 135G  gt  C was already linked to breast and colorectal cancers in certain populations, 172G  gt  T is far less investigated, although sporadic studies showed it could be a prognostic factor for some cancer lesions. The purpose of this study was to investigate RAD51 172G  gt  T polymorphism in Serbian population, its association with colorectal carcinoma, as well as correlation with disease characteristics and response to neoadjuvant chemoradiotherapy. Methods: The 172G  gt  T polymorphism was evaluated by PCR-RFLP method in blood samples of 209 colorectal cancer patients and 43 healthy subjects who served as controls. The distribution of genotypes was also analyzed in respect to several tumor characteristics in cases where histopathological data were available. Results: A significant association between the RAD51 172G  gt  T polymoprhism and desmoplastic reaction of colorectal cancer was demonstrated. The 172G allele was found to be significantly more frequent in patients with more intensive desmoplastic response of the tumor tissue. Conclusions: The results of our study suggest that the 172T allele of RAD51 may be a favorable prognostic factor in Serbian patients with colorectal cancer, although larger prospective studies are required to confirm this finding.",
publisher = "Balkan Union of Oncology (B.U.ON.)",
journal = "Journal of Buon",
title = "Polymorphism RAD51 172G > T in Serbian patients with colorectal cancer",
pages = "940-936",
number = "4",
volume = "23",
url = "https://hdl.handle.net/21.15107/rcub_imagine_1115"
}

Petrović-Sunderić, J., Dragičević, S., Krnjajić, M., Ristanović, M., Nikolić, A.,& Krivokapić, Z.. (2018). Polymorphism RAD51 172G > T in Serbian patients with colorectal cancer. in Journal of Buon
Balkan Union of Oncology (B.U.ON.)., 23(4), 936-940.
https://hdl.handle.net/21.15107/rcub_imagine_1115

Petrović-Sunderić J, Dragičević S, Krnjajić M, Ristanović M, Nikolić A, Krivokapić Z. Polymorphism RAD51 172G > T in Serbian patients with colorectal cancer. in Journal of Buon. 2018;23(4):936-940.
https://hdl.handle.net/21.15107/rcub_imagine_1115 .

Petrović-Sunderić, Jelena, Dragičević, Sandra, Krnjajić, Mina, Ristanović, Momcilo, Nikolić, Aleksandra, Krivokapić, Zoran, "Polymorphism RAD51 172G > T in Serbian patients with colorectal cancer" in Journal of Buon, 23, no. 4 (2018):936-940,
https://hdl.handle.net/21.15107/rcub_imagine_1115 .

TY  - JOUR
AU  - Nikolić, Aleksandra
AU  - Vlajnić, Marina
AU  - Ristanović, Momcilo
AU  - Petrović, Jelena
AU  - Dimitrijević, Ivan
AU  - Krivokapić, Zoran
AU  - Radojković, Dragica
PY  - 2017
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/1036
AB  - Purpose: To analyze if cell free (cf)DNA levels and the presence of KRAS and BRAF mutations in serum could be used as diagnostic biomarkers in patients with primary colorectal cancer (CRC). Methods: This study included 92 individuals who were operated due to primary CRC (N=52;study group) and to hemorrhoids (N=40;control group). Serum cfDNA levels were measured with real-time PCR (RT-PCR) using PicoGreen dsDNA quantitation reagent. Colorectal tissue and related blood and serum samples taken at the time of surgery were subjected to DNA extraction and analysis of KRAS and BRAF mutations based on multiplex SNaPshot assay and DNA sequencing. Results: The average cfDNA concentration was lower in patients of the study group (20 +/- 7 ng/mu L) in comparison to controls (34 +/- 9 ng/mu L) and this difference was statistically significant (p lt 0.001). The SNaPshot analysis detected KRAS c35 mutations in colorectal tumor tissue in 14 cases, but the presence of the mutation was not confirmed in cfD-NA extracted from blood samples of these patients. Conclusions: The level of serum cfDNA in CRC is decreased in comparison to patients with hemorrhoids, which questions the usefulness of cfDNA as cancer biomarker. Also, cfDNA does not appear to be suitable as a source for mutation detection in this disease.
PB  - Balkan Union of Oncology (B.U.ON.)
T2  - Journal of Buon
T1  - Cell-free DNA as biomarker and source for mutation detection in primary colorectal cancer
EP  - 183
IS  - 1
SP  - 178
VL  - 22
UR  - https://hdl.handle.net/21.15107/rcub_imagine_1036
ER  - 

@article{
author = "Nikolić, Aleksandra and Vlajnić, Marina and Ristanović, Momcilo and Petrović, Jelena and Dimitrijević, Ivan and Krivokapić, Zoran and Radojković, Dragica",
year = "2017",
abstract = "Purpose: To analyze if cell free (cf)DNA levels and the presence of KRAS and BRAF mutations in serum could be used as diagnostic biomarkers in patients with primary colorectal cancer (CRC). Methods: This study included 92 individuals who were operated due to primary CRC (N=52;study group) and to hemorrhoids (N=40;control group). Serum cfDNA levels were measured with real-time PCR (RT-PCR) using PicoGreen dsDNA quantitation reagent. Colorectal tissue and related blood and serum samples taken at the time of surgery were subjected to DNA extraction and analysis of KRAS and BRAF mutations based on multiplex SNaPshot assay and DNA sequencing. Results: The average cfDNA concentration was lower in patients of the study group (20 +/- 7 ng/mu L) in comparison to controls (34 +/- 9 ng/mu L) and this difference was statistically significant (p lt 0.001). The SNaPshot analysis detected KRAS c35 mutations in colorectal tumor tissue in 14 cases, but the presence of the mutation was not confirmed in cfD-NA extracted from blood samples of these patients. Conclusions: The level of serum cfDNA in CRC is decreased in comparison to patients with hemorrhoids, which questions the usefulness of cfDNA as cancer biomarker. Also, cfDNA does not appear to be suitable as a source for mutation detection in this disease.",
publisher = "Balkan Union of Oncology (B.U.ON.)",
journal = "Journal of Buon",
title = "Cell-free DNA as biomarker and source for mutation detection in primary colorectal cancer",
pages = "183-178",
number = "1",
volume = "22",
url = "https://hdl.handle.net/21.15107/rcub_imagine_1036"
}

Nikolić, A., Vlajnić, M., Ristanović, M., Petrović, J., Dimitrijević, I., Krivokapić, Z.,& Radojković, D.. (2017). Cell-free DNA as biomarker and source for mutation detection in primary colorectal cancer. in Journal of Buon
Balkan Union of Oncology (B.U.ON.)., 22(1), 178-183.
https://hdl.handle.net/21.15107/rcub_imagine_1036

Nikolić A, Vlajnić M, Ristanović M, Petrović J, Dimitrijević I, Krivokapić Z, Radojković D. Cell-free DNA as biomarker and source for mutation detection in primary colorectal cancer. in Journal of Buon. 2017;22(1):178-183.
https://hdl.handle.net/21.15107/rcub_imagine_1036 .

Nikolić, Aleksandra, Vlajnić, Marina, Ristanović, Momcilo, Petrović, Jelena, Dimitrijević, Ivan, Krivokapić, Zoran, Radojković, Dragica, "Cell-free DNA as biomarker and source for mutation detection in primary colorectal cancer" in Journal of Buon, 22, no. 1 (2017):178-183,
https://hdl.handle.net/21.15107/rcub_imagine_1036 .

TY  - JOUR
AU  - Nikolić, Aleksandra
AU  - Ristanović, Momcilo
AU  - Zivaljević, Vladan
AU  - Divac Rankov, Aleksandra
AU  - Radojković, Dragica
AU  - Paunović, Ivan
PY  - 2015
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/797
AB  - As a key component of the transforming growth factor beta (TGFB) pathway, which regulates the expression of thyroid-specific genes, tumor suppressor SMAD4 is crucial for thyroid development and function. Aberrant expression of SMAD4 in thyroid tumor tissue was reported and mutations affecting the coding region have been detected, but a potential role of mutations in SMAD4 gene regulatory regions remains unexplored. The aim of this study was to analyze SMAD4 gene promoters in thyroid tumors. A total of 76 thyroidectomy specimens were studied, including 42 malignant and 34 benign tumors. The presence of mutations in four SMAD4 gene promoters was analyzed in thyroid tumor tissue and peripheral blood by PCR and DNA sequencing. The expression and intracellular localization of endogenous SMAD4 protein in selected tumor samples was studied by immunostaining and confocal microscopy. Of three novel variants detected, two were within promoter A (-204T/C and -5C/T) and one in promoter D (-180delA). Unlike somatic mutations previously detected in the nearby region, germline mutation -180delA in promoter D doesn't appear to affect SMAD4 expression in the thyroid tumor tissue. However, all newly detected SMAD4 promoter variants affect predicted binding sites of transcription factors involved in cell cycle regulation and should be further characterized functionally. Although not directly involved in carcinogenesis, detected variants may alter SMAD4 transcriptional regulation to some extent. Considering that dosage dependence is of great importance for the role of SMAD4 protein as a tumor suppressor, potential clinical significance of SMAD4 gene promoter mutations is worth further investigation.
PB  - Academic Press Inc Elsevier Science, San Diego
T2  - Experimental and Molecular Pathology
T1  - SMAD4 gene promoter mutations in patients with thyroid tumors
EP  - 103
IS  - 1
SP  - 100
VL  - 99
DO  - 10.1016/j.yexmp.2015.06.005
ER  - 

@article{
author = "Nikolić, Aleksandra and Ristanović, Momcilo and Zivaljević, Vladan and Divac Rankov, Aleksandra and Radojković, Dragica and Paunović, Ivan",
year = "2015",
abstract = "As a key component of the transforming growth factor beta (TGFB) pathway, which regulates the expression of thyroid-specific genes, tumor suppressor SMAD4 is crucial for thyroid development and function. Aberrant expression of SMAD4 in thyroid tumor tissue was reported and mutations affecting the coding region have been detected, but a potential role of mutations in SMAD4 gene regulatory regions remains unexplored. The aim of this study was to analyze SMAD4 gene promoters in thyroid tumors. A total of 76 thyroidectomy specimens were studied, including 42 malignant and 34 benign tumors. The presence of mutations in four SMAD4 gene promoters was analyzed in thyroid tumor tissue and peripheral blood by PCR and DNA sequencing. The expression and intracellular localization of endogenous SMAD4 protein in selected tumor samples was studied by immunostaining and confocal microscopy. Of three novel variants detected, two were within promoter A (-204T/C and -5C/T) and one in promoter D (-180delA). Unlike somatic mutations previously detected in the nearby region, germline mutation -180delA in promoter D doesn't appear to affect SMAD4 expression in the thyroid tumor tissue. However, all newly detected SMAD4 promoter variants affect predicted binding sites of transcription factors involved in cell cycle regulation and should be further characterized functionally. Although not directly involved in carcinogenesis, detected variants may alter SMAD4 transcriptional regulation to some extent. Considering that dosage dependence is of great importance for the role of SMAD4 protein as a tumor suppressor, potential clinical significance of SMAD4 gene promoter mutations is worth further investigation.",
publisher = "Academic Press Inc Elsevier Science, San Diego",
journal = "Experimental and Molecular Pathology",
title = "SMAD4 gene promoter mutations in patients with thyroid tumors",
pages = "103-100",
number = "1",
volume = "99",
doi = "10.1016/j.yexmp.2015.06.005"
}

Nikolić, A., Ristanović, M., Zivaljević, V., Divac Rankov, A., Radojković, D.,& Paunović, I.. (2015). SMAD4 gene promoter mutations in patients with thyroid tumors. in Experimental and Molecular Pathology
Academic Press Inc Elsevier Science, San Diego., 99(1), 100-103.
https://doi.org/10.1016/j.yexmp.2015.06.005

Nikolić A, Ristanović M, Zivaljević V, Divac Rankov A, Radojković D, Paunović I. SMAD4 gene promoter mutations in patients with thyroid tumors. in Experimental and Molecular Pathology. 2015;99(1):100-103.
doi:10.1016/j.yexmp.2015.06.005 .

Nikolić, Aleksandra, Ristanović, Momcilo, Zivaljević, Vladan, Divac Rankov, Aleksandra, Radojković, Dragica, Paunović, Ivan, "SMAD4 gene promoter mutations in patients with thyroid tumors" in Experimental and Molecular Pathology, 99, no. 1 (2015):100-103,
https://doi.org/10.1016/j.yexmp.2015.06.005 . .

TY  - JOUR
AU  - Nikolić, Aleksandra
AU  - Ristanović, Momcilo
AU  - Perović, Vladimir
AU  - Trifunović, Jovanka
AU  - Perović, Milan
AU  - Radojković, Dragica
PY  - 2012
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/566
AB  - Objective: This study was aimed at analyzing alterations in K-ras gene and SMAD4 gene promoter in endometrial carcinoma tissue in Serbian patients. Methods/Materials: The study has encompassed 36 patients whose endometrial cancer tissue samples and peripheral blood samples were analyzed for the presence of alterations in the K-ras gene and the SMAD4 gene promoter. The detection of K-ras codon 12 mutation was performed by polymerase chain reaction restriction fragment length polymorphism technique. Analysis of mononucleotide repeat variants at -462T(15) and -4T(12) of the SMAD4 gene promoter was performed by capillary electrophoresis analysis of DNA fragments fluorescently labeled by polymerase chain reaction. Results: Mutation in codon 12 of the K-ras gene was detected with relatively high frequency of 75.0% (27 of 36 cases). Analysis of 2 mononucleotide repeats in the SMAD4 gene promoter showed that in most cases, haplotypes -462T(15)/-4T(12) and -462T(16)/-4T(12) were present; whereas in one case, a novel haplotype - 462T( 15)/- 4T( 10) was detected. Conclusions: Findings on the role and potential significance of the K-ras codon 12 mutation and SMAD4 gene promoter variants in patients with endometrial carcinoma remain controversial, and their occurrence in this type of cancer should be further investigated.
PB  - BMJ Publishing Group, London
T2  - International Journal of Gynecological Cancer
T1  - Genetic Alterations in SMAD4 and K-ras in Serbian Patients With Endometrial Carcinoma
EP  - 446
IS  - 3
SP  - 442
VL  - 22
DO  - 10.1097/IGC.0b013e31823fabab
ER  - 

@article{
author = "Nikolić, Aleksandra and Ristanović, Momcilo and Perović, Vladimir and Trifunović, Jovanka and Perović, Milan and Radojković, Dragica",
year = "2012",
abstract = "Objective: This study was aimed at analyzing alterations in K-ras gene and SMAD4 gene promoter in endometrial carcinoma tissue in Serbian patients. Methods/Materials: The study has encompassed 36 patients whose endometrial cancer tissue samples and peripheral blood samples were analyzed for the presence of alterations in the K-ras gene and the SMAD4 gene promoter. The detection of K-ras codon 12 mutation was performed by polymerase chain reaction restriction fragment length polymorphism technique. Analysis of mononucleotide repeat variants at -462T(15) and -4T(12) of the SMAD4 gene promoter was performed by capillary electrophoresis analysis of DNA fragments fluorescently labeled by polymerase chain reaction. Results: Mutation in codon 12 of the K-ras gene was detected with relatively high frequency of 75.0% (27 of 36 cases). Analysis of 2 mononucleotide repeats in the SMAD4 gene promoter showed that in most cases, haplotypes -462T(15)/-4T(12) and -462T(16)/-4T(12) were present; whereas in one case, a novel haplotype - 462T( 15)/- 4T( 10) was detected. Conclusions: Findings on the role and potential significance of the K-ras codon 12 mutation and SMAD4 gene promoter variants in patients with endometrial carcinoma remain controversial, and their occurrence in this type of cancer should be further investigated.",
publisher = "BMJ Publishing Group, London",
journal = "International Journal of Gynecological Cancer",
title = "Genetic Alterations in SMAD4 and K-ras in Serbian Patients With Endometrial Carcinoma",
pages = "446-442",
number = "3",
volume = "22",
doi = "10.1097/IGC.0b013e31823fabab"
}

Nikolić, A., Ristanović, M., Perović, V., Trifunović, J., Perović, M.,& Radojković, D.. (2012). Genetic Alterations in SMAD4 and K-ras in Serbian Patients With Endometrial Carcinoma. in International Journal of Gynecological Cancer
BMJ Publishing Group, London., 22(3), 442-446.
https://doi.org/10.1097/IGC.0b013e31823fabab

Nikolić A, Ristanović M, Perović V, Trifunović J, Perović M, Radojković D. Genetic Alterations in SMAD4 and K-ras in Serbian Patients With Endometrial Carcinoma. in International Journal of Gynecological Cancer. 2012;22(3):442-446.
doi:10.1097/IGC.0b013e31823fabab .

Nikolić, Aleksandra, Ristanović, Momcilo, Perović, Vladimir, Trifunović, Jovanka, Perović, Milan, Radojković, Dragica, "Genetic Alterations in SMAD4 and K-ras in Serbian Patients With Endometrial Carcinoma" in International Journal of Gynecological Cancer, 22, no. 3 (2012):442-446,
https://doi.org/10.1097/IGC.0b013e31823fabab . .

TY  - JOUR
AU  - Nikolić, Aleksandra
AU  - Kojić, Snežana
AU  - Knezević, Srbislav
AU  - Krivokapić, Zoran
AU  - Ristanović, Momcilo
AU  - Radojković, Dragica
PY  - 2011
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/543
AB  - Background: The tumor suppressor gene SMAD4 (DPC4) encodes for the common intracellular mediator of the TGF-beta superfamily pathway, which regulates numerous cellular processes, such as cell proliferation, cell differentiation, apoptosis, cell fate and migration. This study was aimed to investigate the presence of genetic variants in SMAD4 gene promoter in malignant pancreatic and colorectal tissue and to analyze their functional consequences. Methods: The study was performed on genomic DNA isolated from malignant tissue samples obtained on surgery from 50 patients with pancreatic carcinoma and 50 patients with colorectal cancer. Screening for mutations within an 800 bp-long fragment of the SMAD4 gene promoter was performed by DNA sequencing and two mononucleotide repeats, at positions -462 and -4, were found to be polymorphic in malignant tissue. The exact number of thymidines in the tracts -462T(15) and -4T(12) was determined by PCR with fluorescently labeled primers followed by capillary electrophoresis. Functional analysis of -462T(15)/-4T(12) haplotypes was performed by luciferase reporter assays. Results: Haplotype -462T(14)/-4T(10) was found in 85% of pancreatic cancer tissues, but it was not present in any of colorectal cancer tissues. Statistically significant reduction (p  lt  0.001) in activity was observed in the haplotype -462T(14)/-4T(10) in comparison with the haplotypes -462T(15)/-4T(12) and -462T(14)/-4T(11). Conclusion: Results of this study indicate that novel genetic variant -4T(10) in the SMAD4 gene promoter affects its activity and that element -4T(12) may play a role in transcriptional regulation of SMAD4 gene expression. Obtained results, though preliminary, also indicate that SMAD4 gene promoter haplotype -462T(14)/-4T(10) may represent a genetic marker of potential relevance for pancreatic and colorectal cancer. The findings of this study should be confirmed by further investigation in these two and other tumors, on larger number of patients and with different tumor stages. Translational research aimed at investigating potential application of mononucleotide repeats -462T(15) and -4T(12) in SMAD4 gene promoter as molecular markers in cancer may also prove useful.
PB  - Elsevier Sci Ltd, Oxford
T2  - Cancer Epidemiology
T1  - Structural and functional analysis of SMAD4 gene promoter in malignant pancreatic and colorectal tissues: Detection of two novel polymorphic nucleotide repeats
EP  - 271
IS  - 3
SP  - 265
VL  - 35
DO  - 10.1016/j.canep.2010.10.002
ER  - 

@article{
author = "Nikolić, Aleksandra and Kojić, Snežana and Knezević, Srbislav and Krivokapić, Zoran and Ristanović, Momcilo and Radojković, Dragica",
year = "2011",
abstract = "Background: The tumor suppressor gene SMAD4 (DPC4) encodes for the common intracellular mediator of the TGF-beta superfamily pathway, which regulates numerous cellular processes, such as cell proliferation, cell differentiation, apoptosis, cell fate and migration. This study was aimed to investigate the presence of genetic variants in SMAD4 gene promoter in malignant pancreatic and colorectal tissue and to analyze their functional consequences. Methods: The study was performed on genomic DNA isolated from malignant tissue samples obtained on surgery from 50 patients with pancreatic carcinoma and 50 patients with colorectal cancer. Screening for mutations within an 800 bp-long fragment of the SMAD4 gene promoter was performed by DNA sequencing and two mononucleotide repeats, at positions -462 and -4, were found to be polymorphic in malignant tissue. The exact number of thymidines in the tracts -462T(15) and -4T(12) was determined by PCR with fluorescently labeled primers followed by capillary electrophoresis. Functional analysis of -462T(15)/-4T(12) haplotypes was performed by luciferase reporter assays. Results: Haplotype -462T(14)/-4T(10) was found in 85% of pancreatic cancer tissues, but it was not present in any of colorectal cancer tissues. Statistically significant reduction (p  lt  0.001) in activity was observed in the haplotype -462T(14)/-4T(10) in comparison with the haplotypes -462T(15)/-4T(12) and -462T(14)/-4T(11). Conclusion: Results of this study indicate that novel genetic variant -4T(10) in the SMAD4 gene promoter affects its activity and that element -4T(12) may play a role in transcriptional regulation of SMAD4 gene expression. Obtained results, though preliminary, also indicate that SMAD4 gene promoter haplotype -462T(14)/-4T(10) may represent a genetic marker of potential relevance for pancreatic and colorectal cancer. The findings of this study should be confirmed by further investigation in these two and other tumors, on larger number of patients and with different tumor stages. Translational research aimed at investigating potential application of mononucleotide repeats -462T(15) and -4T(12) in SMAD4 gene promoter as molecular markers in cancer may also prove useful.",
publisher = "Elsevier Sci Ltd, Oxford",
journal = "Cancer Epidemiology",
title = "Structural and functional analysis of SMAD4 gene promoter in malignant pancreatic and colorectal tissues: Detection of two novel polymorphic nucleotide repeats",
pages = "271-265",
number = "3",
volume = "35",
doi = "10.1016/j.canep.2010.10.002"
}

Nikolić, A., Kojić, S., Knezević, S., Krivokapić, Z., Ristanović, M.,& Radojković, D.. (2011). Structural and functional analysis of SMAD4 gene promoter in malignant pancreatic and colorectal tissues: Detection of two novel polymorphic nucleotide repeats. in Cancer Epidemiology
Elsevier Sci Ltd, Oxford., 35(3), 265-271.
https://doi.org/10.1016/j.canep.2010.10.002

Nikolić A, Kojić S, Knezević S, Krivokapić Z, Ristanović M, Radojković D. Structural and functional analysis of SMAD4 gene promoter in malignant pancreatic and colorectal tissues: Detection of two novel polymorphic nucleotide repeats. in Cancer Epidemiology. 2011;35(3):265-271.
doi:10.1016/j.canep.2010.10.002 .

Nikolić, Aleksandra, Kojić, Snežana, Knezević, Srbislav, Krivokapić, Zoran, Ristanović, Momcilo, Radojković, Dragica, "Structural and functional analysis of SMAD4 gene promoter in malignant pancreatic and colorectal tissues: Detection of two novel polymorphic nucleotide repeats" in Cancer Epidemiology, 35, no. 3 (2011):265-271,
https://doi.org/10.1016/j.canep.2010.10.002 . .